Insight Molecular Diagnostics Inc. Common Stock logo

Insight Molecular Diagnostics Inc. Common Stock (IMDX) Q4 2024 Annual Earnings

IMDX·Reported March 24, 2025·After market close

Insight Molecular Diagnostics Inc. Common Stock reported Q4 2024 revenue of $1.5M, beat analyst consensus of $158.6K by $1.3M. Diluted EPS came in at $0.48, beat the $-0.43 consensus by $0.91.

Revenue
$1.5Mbeat by $1.3M
Consensus: $158.6K
Diluted EPS
$0.48beat by $0.91
Consensus: $-0.43
SEC

SEC Filings

Earnings release8-K not filed yet
Annual report10-K · 0000950170-25-043852

Financial Snapshot

Trailing eight quarters through Q4 2024

View all metrics

Revenue

View metric

Net Income

View metric

Operating Cash Flow

View metric

EPS (Diluted)

View metric

Q4 2024 Earnings FAQ

Common questions about Insight Molecular Diagnostics Inc. Common Stock's Q4 2024 earnings report.

Insight Molecular Diagnostics Inc. Common Stock (IMDX) reported Q4 2024 earnings on March 24, 2025 after market close.

Insight Molecular Diagnostics Inc. Common Stock reported revenue of $1.5M and diluted EPS of $0.48 for Q4 2024.

Revenue beat the consensus estimate of $158.6K by $1.3M. EPS beat the consensus estimate of $-0.43 by $0.91.

You can read the 10-K periodic report (0000950170-25-043852) directly on SEC EDGAR. The filing index links above go to sec.gov.